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Abstract 
Objective: Malignant peripheral nerve sheath tumors (MPNST) are aggressive sarcomas characterized by high 
recurrence rates and early metastases. These tumors arise more frequently within neurofibromatosis type 1 (NF1) 
and present with resistance during standard chemotherapy leading to increased mortality and morbidity in those 
patients. In vitro all‑trans retinoic acid (ATRA) and MEK inhibitors (MEKi) were shown to inhibit tumor proliferation, 
especially when applied in combination. Therefore, we established a nude mouse model to investigate if treatment of 
xenografts derived from NF1 associated S462 and T265 MPNST cells respond to ATRA and the MEKi PD0325901.
Results: We demonstrated that human NF1 associated MPNST derived from S462 but not T265 cells form solid 
subcutaneous tumors in Foxn1 nude mice but not in Balb/c, SHO or Shorn mice. We verified a characteristic staining 
pattern of human MPNST xenografts by immunohistochemistry. Therapeutic effects of ATRA and/or MEKi PD0325901 
on growth of S462 MPNST xenografts in Foxn1 nude mice were not demonstrated in vitro, as we did not observe 
significant suppression of MPNST growth compared with placebo treatment.
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Introduction
Neurofibromatosis type 1 (NF1) is a risk factor for the 
development of malignant peripheral nerve sheath 
tumors (MPNST), which are associated with poor prog-
nosis due to high recurrence and early metastases [1, 2]. 
In NF1, MPNST tend to arise from plexiform neurofi-
bromas as a consequence of NF1 mutations and LOH in 
Schwann cells, leading to activation of Ras signaling [3]. 
Treatment involves surgical removal and chemotherapy. 
However, MPNST display significant resistance to stand-
ard chemotherapy [4, 5], therefore adapted therapies are 
necessary.
Aberrant MAPK cascade activation (Raf/Mek/Erk) 
resulting from neurofibromin inactivation is involved in 
MPNST formation. A recent study detected several MEK 
inhibitors (MEKi) to be active in NF1-associated MPNST 
[6] and the small molecule MEKi and multi kinase 
inhibitor sorafenib has shown anti-tumor properties in 
MPNST in  vitro [6–8]. The effect of MEKi on MPNST 
can be increased by co-treatment with agents such as 
ATRA, BMP2, mTOR kinase inhibitors (AZD8055, 
RAD001), PAK1/2/3 inhibitors and photothermal ther-
apy in  vitro, as well as with PAK inhibitors and photo-
thermal therapy in xenograft models [9–14]. Pre-clinical 
transgenic mouse models demonstrated efficacy of MEKi 
when admitted alone, however increased MEKi proper-
ties were seen when combined with RAD001 [8, 14, 15]. 
Unfortunately, studies testing sorafenib showed only 
minimal response in MPNST patients [16].
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We recently identified a crucial role of retinoic acid 
in MPNST, suggesting a potential therapeutic option as 
shown in other cancers [9, 17, 18]. Combination therapy 
of ATRA is used not only to overcome resistance but 
also to enhance therapeutic effects. Thus, a combination 
of retinoic acid with interferon alpha 2a in progressive 
metastatic renal cell carcinoma, or with histone deacet-
ylase-inhibitor valproic acid in refractory and high-risk 
acute myeloid leukemia, demonstrated beneficial effects 
[19, 20]. In neuroblastoma cells, inhibition of MAPK cas-
cade downstream Ras has been shown to restore ATRA 
responsiveness [21, 22].
In the current study we have attempted to verify 
whether ATRA and MEKi, both alone and in combina-
tion, exhibit efficacy in a xenograft nude mouse model 
for human MPNST, as we have recently demonstrated 
in  vitro [9, 17, 18]. A combination of ATRA and MEKi 
may provide a novel promising therapeutic approach for 
MPNST.
Main text
Materials and methods
Cell culture and colony formation assay
Human MPNST cell lines S462 and T265 were described 
previously [23–26]. Cells were cultured in DMEM 
(4.5 g/L glucose, 2 mM l-glutamine, 10% (v/v) FBS, 100 
U/mL penicillin/streptomycin and 1  mM sodium pyru-
vate). Clonogenic assays were performed as described 
elsewhere with specifications: 300 cells per well were 
seeded in a 6-well plate and incubated for 14 days. [27] 
Following incubation, cells were washed with PBS and 
incubated with staining/fixation solution (6% glutaralde-
hyde/0.5% crystal violet/PBS) for 30 min. Colonies were 
defined as accumulation of > 50 cells. Images were taken 
per well (Olympus SZX12 microscope) using Adobe Pho-
toshop CS5 (Adobe Systems Software Ireland Limited 
2010), and colonies were counted using the cell counter 
tool of ImageJ (NIH United States 2014).
Xenotransplantation and ATRA quantification
Experiments were approved by the federal state author-
ity of nature, environment and consumer protection of 
Nordrhein-Westfalen (“Landesamt für Natur, Umwelt 
und Verbraucherschutz Nordrhein-Westfalen“, LANUV) 
(27.08.2013, reference 84-02.04.2013.A275). Balb/c Nude 
(Balb/cAnNRj-Foxn1nu/Foxn1nu, Janvier), Foxn1 (Nu/
Nu) Nude (Crl:NU-Foxn1nu, Charles River),  SHO® 
(SCID Hairless Outbred, Crl:SHO-PrkdcscidHrhr, 
Charles River) and Shorn (ShrN NOD SCID, NOD.Cg-
PrkdcscidHrhr/NCrHsd, Harlan) mice were scheduled 
for xenotransplantations. Female mice were housed in 
single cages and all strains lacked hair and T cells.  SHO® 
and Shorn mice also lacked B cells, and Shorn mice 
additional partially lacked NK cells. We followed pub-
lished criteria for generating xenografts.
At study initiation nude mice were 5–7  weeks old. A 
total of 5 × 106 cells (T265, S462) within 30% Matrigel™ 
(Corning, GFR)/DMEM were implanted by subcutane-
ous injection (150 μL) into the right and/or left flank.
Blood was collected on day 21 of treatment, 2–3 h after 
oral application. Plasma was extracted immediately from 
blood by centrifugation (1000×g, 5 min). ATRA plasma 
levels were analyzed as described elsewhere [28].
Pharmacological treatment, tumor volume quantification 
and preparation
Daily oral treatment started 42  days after subcutaneous 
implantation over a period of 28  days. Ten mice were 
treated with ATRA (15  mg/kg) or PD0325901 (10  mg/
kg). Intake was scored (1 = full intake, 0.5 = incomplete 
intake, 0 = no intake) and mean values were calculated. 
Tumor volume was measured three times a week using 
a digital caliper and calculated according to the formula: 
v = L × W2 (π/6) (L-longest diameter, W-width) [29].
Intra-cardiac perfusion was used for euthanization of 
mice. Under deep anaesthesia (1.8% (v/v) ketamine and 
0.3% xylazine in PBS), peritoneal cavity, thorax, left heart 
ventricle and the right heart atrium were opened, and 
10 mL PBS were injected into the ventricle. For fixation 
of mice tissues injection of 10 mL 4% paraformaldehyde 
followed PBS intra-cardiac perfusion. Tumors were dis-
sected and stored in 4% PFA for 24 h followed by paraffin 
embedding. Tumors were dehydrated in increasing alco-
hol concentrations in a Tissue-Tek VIP system (Sakura) 
and embedded in paraffin. Immunohistochemistry of 
MPNST xenografts was performed using antibodies 
against S100 (monoclonal, mouse, 10  μg/mL, Ventana 
S100-4C4.9) to demonstrate human Schwann cell ori-
gin, anti-Ki67 (monoclonal, mouse, 0.4  μg/mL, Ventana 
Ki-67-30.9) to evaluate proliferation fraction, anti-CD34 
(monoclonal, mouse, 0.8  μg/mL, Ventana QBEnd/10) 
to demonstrate vessel and stem cell formation, anti-
p53 (monoclonal, mouse, Ventana Bp-53-11), anti-p16 
(monoclonal, mouse, 1 μg/mL, Ventana 725-4713), anti-
vimentin (vimentin, monoclonal, mouse, 2.5 μg/mL, Ven-
tana V9 and anti-actin (monoclonal, mouse, 0.02 μg/mL, 
Cell Margue 1A4). Staining was visualized using the ultra-
View™ Universal Alkaline Phosphatase Red Detection Kit 
(Ventana, A-PAP method). Staining was performed in 
the automated staining system Ventana BenchMark XT 
according to the standard protocols.
Statistical analysis
ANOVA followed by post hoc t test was used to com-
pare differences between groups. Kruskal–Wallis test was 
applied to compare groups of 4 mice for weight gain. A p 
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value < 0.05 was defined to be significant. The SPSS pro-
gram (IBM SPSS Statistics Standard) was applied.
Results
We investigated four strains and cell lines T265 and S462. 
To determine tumor formation capability colony forma-
tion assays were performed and yielded 42 ± 6 colonies of 
T265 cells and 21 ± 5 colonies of S462 cells from 300 cells 
plated.
Once clonogenic potential had been demonstrated, we 
tested strains for tumor formation capability. 2 ×  106, 5 
×  106, and 10 ×  106 MPNST cells were subcutaneously 
transplanted into the right flank of Balb/c mice (6 groups 
of 4–5 mice). After 8 weeks tumor volumes did not reach 
70  mm3. Differences with respect to cell number were 
not seen. To test other strains for xenotransplantation, 
5 ×  106 MPNST cells were transplanted into the right 
and left flank (2 mice/strain, 2 transplants/mouse) of 
Foxn1, SHO and Shorn mice, and growth was monitored 
for 8  weeks. Transplants of T265 cells did not generate 
tumors in Foxn1 mice whereas SHO and Shorn mice 
developed one flank tumor each (2 tumors/4 transplants) 
with only 1 tumor gaining a volume > 70 mm3. Transplan-
tation of S462 cells resulted in complete tumor devel-
opment in all Foxn1 mice (4/4), and all tumors reached 
volumes > 70  mm3 48  days after transplantation. SHO 
mice developed 3/4 tumors, but volumes did not reach 
70  mm3. Only one tumor in Shorn mice (1/4) below 
70  mm3 was seen. MPNST pattern of xenografts was 
confirmed histologically.
Beforehand, we had checked in Balb/c mice if appli-
cation of ATRA and MEKi was tolerated and if oral 
application was sufficiently fast and complete. Oral 
administration of ATRA was prescribed by the veterinar-
ian. Oral intake of MEKi is published in literature [15]. 
In our analysis intake of 0.2 g chocolate with ATRA was 
identical to chocolate with DMSO (placebo group) (mean 
intake: 1). Due to its strong flavor, the MEKi had to be 
served with 0.2  g peanut butter, still 1 mouse showed 
low intake (< 0.5). ATRA and MEKi treatment as well as 
combination was also-pre-checked to determine poten-
tial side effects in groups of 4 mice per agent as well as 
placebo (DMSO). We did not observe major side effects, 
in fact temporary unilateral eye irritation was the only 
impairment seen independently of treatment in all 
groups (sparing SHO mice) which did not meet the cri-
teria for exclusion. None of the mice presented with sig-
nificant weight loss (> 20%): by Kruskal–Wallis test we 
did not detect significant differences due to treatment 
regimens (placebo/chocolate, ATRA/chocolate, MEKi/
peanut butter, control/normal diet). Macroscopy and his-
tological examination of brain, spleen, kidney, stomach, 
liver and heart of all animals was without any pathology 
at the end of experiments in all animals.
From the above experiments, we selected S462 cells for 
transplantation into the right flank of Foxn1 mice. At day 
42 after transplantation placebo, ATRA and MEKi, both 
alone and in combination, were administered until day 
68. At day 42 mean tumor volume of the placebo group 
(n = 10) was 87.6 (± 31.4 SD)  mm3, of the ATRA group 
(n = 9) was 106.2 (± 11.9 SD)  mm3, and the MEKi group 
(n = 10) was 99.2 (± 51.3 SD).
ATRA plasma levels following ATRA administration 
were determined on day 21. Levels observed in the ATRA 
group were 2.76  µM (mean ± 2.07; range 0.41–5.84), 
compared to levels below the detection limit of 0.07 μM 
in the placebo group. These exposures in treated animals 
were consistent with levels of 1–5 μM observed in human 
acute promyelocytic leukemia patients.
Unexpectedly, Foxn1 mice of ATRA-MEKi combina-
tion group did not show sufficient food intake as we had 
trialed in Balb/c: Compared to placebo group (intake: 1 
during the whole treatment period) ATRA/MEKi group 
showed low intake rates. We therefore exclude this group 
from experiments.
Mean tumor volume at the end of experiments (day 
68) were as follows: 90.7 (± 22.2 SD)  mm3 in the placebo 
group (n = 10), 96.0 (± 19.9 SD)  mm3 in the ATRA group 
(n = 9), and 108.3 (± 34.1 SD) in the MEKi group (n = 10). 
All data are shown in Additional file 1. Comparing mean 
tumor volumes at the end of experiments revealed no 
statistically significant differences as compared to the 
untreated placebo group (Figs.  1, 2). Mean tumor vol-
umes were higher in the ATRA group at the start of the 
experiments and a decrease in tumor volumes was seen 
following treatment, nevertheless differences between 
first and last day of treatment were statistically not signif-
icant. The animals treated with MEKi also did not show 
significant changes of tumor volumes. Principally, we 
defined tumor regression (that may have been observed 
independently from the poor tumor growth characteris-
tics of the placebo) as ≥ 50% reduction of volume com-
pared to volume at the start of treatment. However, no 
treatment group or single animals met this criterion.
Finally, S462 xenografts were subjected to HE stain and 
immunohistochemistry. Typical MPNST morphology 
was confirmed by neuropathological examination (Fig. 3). 
Marked inflammation was not seen. Areas of low cellu-
lar density and myxoid change or adipose tissue within 
tumors that were otherwise highly cellular indicating 
focal differentiation within the MPNST (Triton tumor-
like) was identified in some cases. Expression of S100 
and a strong nuclear expression of p53 were detected 
indicating additional TP53 mutations in MPNST and no 
genotype change of the transplants. Nuclear expression 
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of Ki-67 reached 40–45%. As MPNST typically acquire 
CDKN2A mutations transplanted S462 cells demon-
strated loss of p16 as well. To exclude minor histopatho-
logical changes all tumors of animals were investigated 
using H&E staining and immunohistochemistry in this 
study, tumors of the main experiments were also cutted 
in 3 µm series for evaluation.
Conclusions
In contrast to other in  vivo studies, we observed that 
neither ATRA nor MEKi therapy significantly reduced 
growth of S462 derived xenografts in Fox1 nude 
mice. Due to several limitations we expect that tumor 
formation capability, agent administration, mouse strain 
and treatment period are critical parameters, that need to 
be exhaustedly examined before excluding MEKi and/or 
ATRA treatment as sufficient agents against MPNST.
Limitations
  • Reduced acceptance of oral administration led to 
exclusion of an important subgroup (ATRA/MEKi) 
from our study. Thus, intraperitoneal application that 
allows exact dose control may be more suitable in 
future experiments.
  • Although tumor formation capability of S462 cells 
was reliably pre-tested in Foxn1 mice, tumor volumes 
did not reach values described in literature (750–
2500 mm3) [15, 30, 31] in almost three studies with 
S462 cells or with other MPNST cell lines [29, 30, 32, 
33]. Thus, selecting more suitable mouse strains and 
longer treatment periods may improve validity.
  • Tumor growth was not seen in Balb/c mice at all, 
although those have been successfully used in sev-
eral ATRA treatment studies for human tumor xen-
ografts including medulloblastoma, melanoma and 
others [34, 35]. T265 and S462 MPNST cells seem 
not to bear sufficient tumor formation capacity in 
this otherwise well investigated strain. Thus, selec-
tion of other MPNST cell lines seems necessary to 
test the hypothesis (at least in Balb/c mice).
  • Measuring small tumors with a caliper hampers sig-
nificance. MRI or ultrasound may be more suitable to 
control tumor size.
Fig. 1 Growth characteristics (mean tumor volumes) of S462 MPNST xenografts are shown for ATRA and MEKi treatment and placebo
Fig. 2 Growth characteristics of S462 MPNST xenografts in nude 
mice demonstrating tumor volumes at start (day 42) and end of 
therapy (day 68)
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Fig. 3 Histomorphological features S462 MPNST xenografts. A HE staining of a highly cellular MPNST xenograft. B Tumor cells stain positive S100 
(nuclear and cytoplasmatic. C A high Ki‑67 labelling index of 45% was determined by MIB‑1 staining. D Staining for CD34 was found to be positive 
for single cells of the xenograft. E Staining for actin was present only in single cells. F HE staining of a hyper‑cellular MPNST xenograft. G Strong 
nuclear p53 expression and H absence of p16 expression
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  • Insufficient growth characteristics may be due to Tri-
ton tumor-like differentiation within MPNST xeno-
grafts, however we cannot provide detailed investiga-
tions.
Additional file
Additional file 1. Mean tumor volumes. Description of data: Mean 
volumes of transplanted MPNST (mm³) of two treatment groups (mice 
treated with ATRA and with MEKi) and of placebo group. Tumors were 
measured from day 7 until day 68 post transplantation. Treatment started 
at day 42. Average volumes and standard deviation over the whole group 
per day as well as difference of volumes between day 42 and 68 are given.
Abbreviations
ATRA : all‑trans retinoic acid; BMP2: bone morphogenetic Protein 2; DMEM: 
Dulbecco’s modified eagle’s medium; ERK: extracellular‑signal regulated 
kinase; LOH: loss of heterozygosity; MAPK: mitogen‑activated protein kinase; 
MEK: mitogen‑activated protein kinase; MEKi: MEK inhibitor; mTOR: mecha‑
nistic target of rapamycin; MPNST: malignant peripheral nerve sheath tumor; 
NF1: neurofibromatosis type 1; PAK: p21‑Activated Kinase; RAF: rapidly acceler‑
ated fibrosarcoma; RAS: rat sarcoma.
Authors’ contributions
The study was planned and coordinated by AH, SFH and VoS. Animal experi‑
ments were carried out by SFH, LC, VS, and VoS. Quantification of ATRA 
plasma level was performed by GV, PB and MZ. GV organized and analyzed 
quantification of ATRA plasma level. Histological evaluation was done by AH, 
SFH and LC. Data collection, analysis, interpretation and manuscript writing 
was performed by AH, FSH and LC. VFM supplied MPNST cells and revised the 
manuscript critically for intellectual content. All authors read and approved 
the manuscript.
Author details
1 Institute of Neuropathology, University Hospital Münster, Münster, Germany. 
2 Northern Institute for Cancer Research, Newcastle University, Newcastle 
upon Tyne, UK. 3 Clinics and Polyclinics of Neurology, University Hospital 
Hamburg‑Eppendorf, Hamburg, Germany. 4 Institute of Pathology, Health Care 
Center, Brandenburg Hospital, Brandenburg Medical School Theodor Fontane, 
Brandenburg, Germany. 
Acknowledgements
We highly appreciate help by Eric Tietz and the group of Prof. Tanja Kuhlmann 
(Institute of Neuropathology, University Hospital Münster) for technical assis‑
tance and advice concerning mouse experiments. We thank Elana Walther 
for technical assistance concerning immunological staining and histological 
workup. We thank S. Frahm, M. Spyra, L. Kluwe for providing NF1 associated 
MPNST cell lines as well as for advice concerning experimental procedures. We 
appreciate encouragement of our work by H. J. Galla (Institute of Biochemistry, 
University of Münster).
Competing interests
The authors declare that they have no competing interests.
Availability of data and material
All data generated or analyzed during this study are included in this published 
article and its Additional file 1.
Consent for publication
Not applicable.
Ethics approval and consent to participate
Material from patients was not included into the study. Animal experiments 
were approved by the federal state authority of nature, environment and 
consumer protection of Nordrhein‑Westfalen (“Landesamt für Natur, Umwelt 
und Verbraucherschutz Nordrhein‑Westfalen“, LANUV) (27.08.2013, reference 
84‑02.04.2013.A275).
Funding
The study was supported by a grant of Nothing is forever e.V. (604242).
Publisher’s Note
Springer Nature remains neutral with regard to jurisdictional claims in pub‑
lished maps and institutional affiliations.
Received: 1 June 2018   Accepted: 20 July 2018
References
 1. Ducatman BS, Scheithauer BW, Piepgras DG, Reiman HM, Ilstrup DM. 
Malignant peripheral nerve sheath tumors. A clinicopathologic study of 
120 cases. Cancer. 1986;57(10):2006–21.
 2. Ferner RE, Gutmann DH. International consensus statement on malignant 
peripheral nerve sheath tumors in neurofibromatosis. Cancer Res. 
2002;62(5):1573–7.
 3. Weiss S, Goldblum J. Soft tissue tumours. 4th ed. Elsevier: Mosby; 2008. p. 
583–94.
 4. Kroep JR, Ouali M, Gelderblom H, Le Cesne A, Dekker TJ, Van Glabbeke 
M, et al. First‑line chemotherapy for malignant peripheral nerve sheath 
tumor (MPNST) versus other histological soft tissue sarcoma subtypes 
and as a prognostic factor for MPNST: an EORTC soft tissue and bone 
sarcoma group study. Ann Oncol. 2011;22(1):207–14.
 5. Zehou O, Fabre E, Zelek L, Sbidian E, Ortonne N, Banu E, et al. Chemo‑
therapy for the treatment of malignant peripheral nerve sheath tumors 
in neurofibromatosis 1: a 10‑year institutional review. Orphanet J Rare Dis. 
2013;8:127.
 6. Guo J, Grovola MR, Xie H, Coggins GE, Duggan P, Hasan R, et al. Compre‑
hensive pharmacological profiling of neurofibromatosis cell lines. Am J 
Cancer Res. 2017;7(4):923–34.
 7. Ambrosini G, Cheema HS, Seelman S, Teed A, Sambol EB, Singer S, 
et al. Sorafenib inhibits growth and mitogen‑activated protein kinase 
signaling in malignant peripheral nerve sheath cells. Mol Cancer Ther. 
2008;7(4):890–6.
 8. Dodd RD, Mito JK, Eward WC, Chitalia R, Sachdeva M, Ma Y, et al. NF1 dele‑
tion generates multiple subtypes of soft‑tissue sarcoma that respond to 
MEK inhibition. Mol Cancer Ther. 2013;12(9):1906–17.
 9. Fischer‑Huchzermeyer S, Dombrowski A, Wilke G, Stahn V, Streubel A, 
Mautner VF, et al. MEK inhibitors enhance therapeutic response towards 
ATRA in NF1 associated malignant peripheral nerve sheath tumors 
(MPNST) in‑vitro. PLoS ONE. 2017;12(11):e0187700.
 10. Ahsan S, Ge Y, Tainsky MA. Combinatorial therapeutic targeting of BMP2 
and MEK‑ERK pathways in NF1‑associated malignant peripheral nerve 
sheath tumors. Oncotarget. 2016;7(35):57171–85.
 11. Semenova G, Stepanova DS, Dubyk C, Handorf E, Deyev SM, Lazar AJ, 
et al. Targeting group I p21‑activated kinases to control malignant 
peripheral nerve sheath tumor growth and metastasis. Oncogene. 
2017;36(38):5421–31.
 12. Sweeney EE, Burga RA, Li C, Zhu Y, Fernandes R. Photothermal therapy 
improves the efficacy of a MEK inhibitor in neurofibromatosis type 
1‑associated malignant peripheral nerve sheath tumors. Sci Rep. 
2016;6:37035.
 13. Varin J, Poulain L, Hivelin M, Nusbaum P, Hubas A, Laurendeau I, et al. Dual 
mTORC1/2 inhibition induces anti‑proliferative effect in NF1‑associated 
plexiform neurofibroma and malignant peripheral nerve sheath tumor 
cells. Oncotarget. 2016;7(24):35753–67.
 14. Watson AL, Anderson LK, Greeley AD, Keng VW, Rahrmann EP, Halfond 
AL, et al. Co‑targeting the MAPK and PI3 K/AKT/mTOR pathways in two 
genetically engineered mouse models of schwann cell tumors reduces 
tumor grade and multiplicity. Oncotarget. 2014;5(6):1502–14.
 15. Jessen WJ, Miller SJ, Jousma E, Wu J, Rizvi TA, Brundage ME, et al. MEK 
inhibition exhibits efficacy in human and mouse neurofibromatosis 
tumors. J Clin Invest. 2013;123(1):340–7.
 16. Maki RG, D’Adamo DR, Keohan ML, Saulle M, Schuetze SM, Undevia SD, 
et al. Phase II study of sorafenib in patients with metastatic or recurrent 
sarcomas. J Clin Oncol. 2009;27(19):3133–40.
Page 7 of 7Fischer‑Huchzermeyer et al. BMC Res Notes  (2018) 11:520 
•
 
fast, convenient online submission
 •
  
thorough peer review by experienced researchers in your field
• 
 
rapid publication on acceptance
• 
 
support for research data, including large and complex data types
•
  
gold Open Access which fosters wider collaboration and increased citations 
 
maximum visibility for your research: over 100M website views per year •
  At BMC, research is always in progress.
Learn more biomedcentral.com/submissions
Ready to submit your research ?  Choose BMC and benefit from: 
 17. Fischer‑Huchzermeyer S, Dombrowski A, Hagel C, Mautner VF, Schit‑
tenhelm J, Harder A. The cellular retinoic acid binding protein 2 promotes 
survival of malignant peripheral nerve sheath tumor cells. Am J Pathol. 
2017;187(7):1623–32.
 18. Fischer‑Huchzermeyer S. The role of retinoic acid and CRABP2 in 
NF1‑associated peripheral nerve sheath tumours. Thesis, University of 
Muenster, Germany; 2014.
 19. Aass N, De Mulder PH, Mickisch GH, Mulders P, van Oosterom AT, van 
Poppel H, et al. Randomized phase II/III trial of interferon Alfa‑2a with and 
without 13‑cis‑retinoic acid in patients with progressive metastatic renal 
cell Carcinoma: the European Organisation for Research and Treatment 
of Cancer Genito‑Urinary Tract Cancer Group (EORTC 30951). J Clin Oncol. 
2005;23(18):4172–8.
 20. Cimino G, Lo‑Coco F, Fenu S, Travaglini L, Finolezzi E, Mancini M, et al. 
Sequential valproic acid/all‑trans retinoic acid treatment reprograms 
differentiation in refractory and high‑risk acute myeloid leukemia. Cancer 
Res. 2006;66(17):8903–11.
 21. Huang S, Laoukili J, Epping MT, Koster J, Holzel M, Westerman BA, et al. 
ZNF423 is critically required for retinoic acid‑induced differentiation and 
is a marker of neuroblastoma outcome. Cancer Cell. 2009;15(4):328–40.
 22. Holzel M, Huang S, Koster J, Ora I, Lakeman A, Caron H, et al. NF1 is 
a tumor suppressor in neuroblastoma that determines retinoic acid 
response and disease outcome. Cell. 2010;142(2):218–29.
 23. Frahm S, Mautner VF, Brems H, Legius E, Debiec‑Rychter M, Friedrich RE, 
et al. Genetic and phenotypic characterization of tumor cells derived 
from malignant peripheral nerve sheath tumors of neurofibromatosis 
type 1 patients. Neurobiol Dis. 2004;16(1):85–91.
 24. Holtkamp N, Okuducu AF, Mucha J, Afanasieva A, Hartmann C, Atallah I, 
et al. Mutation and expression of PDGFRA and KIT in malignant peripheral 
nerve sheath tumors, and its implications for imatinib sensitivity. Carcino‑
genesis. 2006;27(3):664–71.
 25. Lee PR, Cohen JE, Tendi EA, Farrer R, Dev GH, Becker KG, et al. Tran‑
scriptional profiling in an MPNST‑derived cell line and normal human 
Schwann cells. Neuron Glia Biol. 2004;1(2):135–47.
 26. Spyra M, Kluwe L, Hagel C, Nguyen R, Panse J, Kurtz A, et al. Cancer stem 
cell‑like cells derived from malignant peripheral nerve sheath tumors. 
PLoS ONE. 2011;6(6):e21099.
 27. Franken NA, Rodermond HM, Stap J, Haveman J, van Bree C. Clonogenic 
assay of cells in vitro. Nat Protoc. 2006;1(5):2315–9.
 28. Armstrong JL, Taylor GA, Thomas HD, Boddy AV, Redfern CP, Veal GJ. 
Molecular targeting of retinoic acid metabolism in neuroblastoma: the 
role of the CYP26 inhibitor R116010 in vitro and in vivo. Br J Cancer. 
2007;96(11):1675–83.
 29. Patel AV, Eaves D, Jessen WJ, Rizvi TA, Ecsedy JA, Qian MG, et al. Ras‑driven 
transcriptome analysis identifies aurora kinase A as a potential malignant 
peripheral nerve sheath tumor therapeutic target. Clin Cancer Res. 
2012;18(18):5020–30.
 30. Demestre M, Terzi MY, Mautner V, Vajkoczy P, Kurtz A, Pina AL. Effects of 
pigment epithelium derived factor (PEDF) on malignant peripheral nerve 
sheath tumours (MPNSTs). J Neurooncol. 2013;115(3):391–9.
 31. Antoszczyk S, Spyra M, Mautner VF, Kurtz A, Stemmer‑Rachamimov 
AO, Martuza RL, et al. Treatment of orthotopic malignant peripheral 
nerve sheath tumors with oncolytic herpes simplex virus. Neuro Oncol. 
2014;16(8):1057–66.
 32. Mahller YY, Vaikunth SS, Ripberger MC, Baird WH, Saeki Y, Cancelas 
JA, et al. Tissue inhibitor of metalloproteinase‑3 via oncolytic herpes‑
virus inhibits tumor growth and vascular progenitors. Cancer Res. 
2008;68(4):1170–9.
 33. Demestre M, Herzberg J, Holtkamp N, Hagel C, Reuss D, Friedrich RE, et al. 
Imatinib mesylate (Glivec) inhibits Schwann cell viability and reduces the 
size of human plexiform neurofibroma in a xenograft model. J Neuroon‑
col. 2009;98(1):11–9.
 34. Li S, Gao Y, Pu K, Ma L, Song X, Liu Y. All‑trans retinoic acid enhances 
bystander effect of suicide‑gene therapy against medulloblastomas. 
Neurosci Lett. 2011;503(2):115–9.
 35. Siddikuzzaman, Berlin GV. Evaluation of immunomodulatory and antitu‑
mor activity of all trans retinoic acid (ATRA) in solid tumor bearing mice. 
Immunopharmacol Immunotoxicol. 2013;35(1):110–8.
